Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/98414
Title: | HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer | Authors: | Koh, Elisa Pang, Cindy Soh, Lay-Tin Wang, Jin Ho, Tew-Hong Tay, Sun-Kuie Lim-Tan, Soo-Kim Lim, Kiat-Hon Chia, John Whay-Kuang Goh, Liang-Kee Chay, Wen-Yee Chew, Sung-Hock Ong, Whee-Sze Busmanis, Inny Li, Xinyun Thung, Sharyl Ngo, Lynette Lim, Sheow-Lei Lim, Yong-Kuei Chia, Yin-Nin |
Keywords: | Biological Sciences | Issue Date: | 2013 | Source: | Chay, W. Y., Chew, S. H., Ong, W. S., Busmanis, I., Li, X., Thung, S., et al. (2013). HER2 Amplification and Clinicopathological Characteristics in a Large Asian Cohort of Rare Mucinous Ovarian Cancer. PLoS ONE, 8(4), e61565. | Series/Report no.: | PLoS ONE | Abstract: | Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8–89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66–4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers. | URI: | https://hdl.handle.net/10356/98414 http://hdl.handle.net/10220/18445 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0061565 | Schools: | School of Biological Sciences | Rights: | © 2013 The Authors. This paper was published in PLoS ONE and is made available as an electronic reprint (preprint) with permission of the authors. The paper can be found at the following official DOI: [http://dx.doi.org/10.1371/journal.pone.0061565]. One print or electronic copy may be made for personal use only. Systematic or multiple reproduction, distribution to multiple locations via electronic or other means, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper is prohibited and is subject to penalties under law. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
Appears in Collections: | SBS Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
HER2 Amplification and Clinicopathological Characteristics in a Large Asian Cohort of Rare Mucinous Ovarian Cancer.pdf | 489.73 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
10
39
Updated on Mar 24, 2024
Web of ScienceTM
Citations
10
34
Updated on Oct 28, 2023
Page view(s) 20
662
Updated on Mar 28, 2024
Download(s) 10
347
Updated on Mar 28, 2024
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.